載入中
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
一般交易時段
US$3.735
−US$0.095 · -2.48%
盤中時間採用ET。市場資料可能有所延遲。
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
日內區間
目前US$3.735
52週區間
目前US$3.735
盤中時間採用ET。市場資料可能有所延遲。
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
日內區間
目前US$3.735
52週區間
目前US$3.735
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 782.6萬 USD | 1872萬 USD | 3124.9萬 USD | 2975.2萬 USD | 676.1萬 USD |
| 銷貨成本 | 209.1萬 USD | 279.2萬 USD | 1808.1萬 USD | 1196萬 USD | 471.3萬 USD |
| 毛利 | 573.5萬 USD | 1592.8萬 USD | 1316.8萬 USD | 1779.2萬 USD | 204.8萬 USD |
| 研究與開發 | 5264.5萬 USD | 3358.6萬 USD | 9838.4萬 USD | 7781.3萬 USD | 4381.3萬 USD |
| 銷售、一般及管理費用 | 2197.2萬 USD | 2220.3萬 USD | 3109.8萬 USD | 2513.3萬 USD | 2361.9萬 USD |
| 營業費用 | 8211萬 USD | 1.58億 USD | 1.11億 USD | 1.08億 USD | 9177.1萬 USD |
| 利息收入 | 763.7萬 USD | 795.3萬 USD | — | — | — |
| 折舊和攤銷 | 45.4萬 USD | 80.7萬 USD | 86.3萬 USD | 79.7萬 USD | 92.3萬 USD |
| 營業利益 | −7637.5萬 USD | −1.42億 USD | −9735.7萬 USD | −8985.4萬 USD | −8972.3萬 USD |
| 淨利 | −6492.3萬 USD | −1.32億 USD | −8848.1萬 USD | −8690.8萬 USD | −9086.5萬 USD |
公司資料更新於 2026年10月12日。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2567.23萬0.00%2.3兆 USD0.03%US$381.74-0.05%
iShares Russell 2000 ETFIWM1193.08萬0.02%787.4億 USD0.19%US$278.49-0.16%
Vanguard Extended Market ETFVXF887.06萬0.01%954億 USD0.05%US$234.16-0.36%
Vanguard Russell 2000 ETFVTWO412.24萬0.02%180億 USD0.06%US$112.49-0.16%
State Street SPDR S&P Pharmaceuticals ETFXPH391.39萬0.85%4.62億 USD0.35%US$64.375-0.43%
iShares Russell 2000 Growth ETFIWO366.57萬0.03%139.17億 USD0.24%US$354.64-0.60%
iShares Biotechnology ETFIBB334.87萬0.03%108.2億 USD0.44%US$204.81-0.81%
Fidelity Enhanced Small Cap ETFFESM320.01萬0.05%64.1億 USD0.28%US$45.375-0.19%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
